The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mortality Reductions Based on AUD/Heavy Alcohol Use, HIV Risk, and Cardiovascular Risk

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05828849
Recruitment Status : Not yet recruiting
First Posted : April 25, 2023
Last Update Posted : March 1, 2024
Sponsor:
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Information provided by (Responsible Party):
NYU Langone Health

Brief Summary:
The purpose of this research study is to investigate if a personalized intervention including parts such as navigation (focus on patient outreach efforts, missed and completed encounters), personalization (individual health benefits) and compensation (value health-related costs borne by patients) will help people reduce their chances of dying from preventable causes, including heart attacks, strokes, drinking alcohol, substance abuse, HIV, and other conditions.

Condition or disease Intervention/treatment Phase
Cardiovascular Disease Alcohol Use Disorder HIV Risk Substance Use Disorders Behavioral: Navigation, compensation, and personalization Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Can a Radical Transformation of Preventive Care Reduce Mortality by 20% in Low Socioeconomic (SES) Populations? Preparatory Work Focusing on Alcohol Use Disorder (AUD)/Heavy Alcohol Use, HIV Risk, and Cardiovascular Risk
Estimated Study Start Date : April 15, 2024
Estimated Primary Completion Date : July 2025
Estimated Study Completion Date : July 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Alcohol HIV

Arm Intervention/treatment
Experimental: Low SES Population - Intervention
Participants receive the study intervention, composed of navigation, compensation, and personalization for study participants. The intervention will be administered in person to the participants recruited for the study and will be administered by peer navigators who will be trained on Motivational Interviewing (MINT) techniques.
Behavioral: Navigation, compensation, and personalization
The study intervention is composed of navigation, compensation, and personalization. Navigation refers to reducing barriers posed by fragmentation of health and social systems. Compensation refers to reimbursement of out-of-pocket expenses to offset dependent care, time costs, and travel expenditures necessary to access care for the different conditions and goals of the intervention. Personalization refers to preventative interventions that are personalized based on individual for potential benefit.

No Intervention: Low SES Population - No Intervention
Participants receive no intervention components of navigation, compensation, and personalization. Participants will receive their normal medical care through regular doctor visits without any intervention or personalization.



Primary Outcome Measures :
  1. Change in Alcohol Use Disorders Identification Test (AUDIT) Score [ Time Frame: Baseline, Month 12 ]
    10-item self-assessment of alcohol use disorders. Items are rated on a scale from 0 to 4. The total score is the sum of responses and ranges from 0-40; higher scores indicate it is more likely the patient's drinking is affecting their health and safety.

  2. Change in Alcohol Use Disorders Identification Test-Concise (AUDIT-C) [ Time Frame: Baseline, Month 12 ]
    4-item self-assessment of alcohol use disorders. Items are rated on a scale from 0 to 4. The total score is the sum of responses and ranges from 0-12; higher scores indicate it is more likely the patient's drinking is affecting their health and safety.

  3. Change in National Institute on Alcohol Abuse and Alcoholism (NIAAA) single-item alcohol use screen (NIAAA-1) [ Time Frame: Baseline, Month 12 ]
    The NIAAA-1 asks participants how many times in the past year they have had four or more drinks (for females) or five or more drinks (for males) in a day. The responses are 0 (never), 1 (Less than once a month), 2 (One to three times per month), 3 (One to three times per week) and 4 (More than three times per week). The total score is the item response and ranges from 0-4; higher scores indicate greater unhealthy alcohol use.

  4. Change in 2-Week Timeline Follow-Back (TLFB) for Alcohol Use [ Time Frame: Baseline, Month 12 ]
    The TLFB allows participants to indicate how many drinks they have had over the previous two weeks.

  5. Change in Ethanol Glucuronide (ETG) Levels [ Time Frame: Baseline, Month 12 ]
    ETG (ng/ml) will be measured via urine test.

  6. Change in Phosphatidylethanol (PeTH) Levels [ Time Frame: Baseline, Month 12 ]
    PeTH (ng/ml) will be measured via blood test.

  7. Change in CDC HIV Incidence Risk Index Score [ Time Frame: Baseline, Month 12 ]
    3-item assessment of HIV risk among people who inject drugs. The total score ranges from 0 to 100; higher scores indicate greater risk of HIV.

  8. Change in American Heart Association/American College of Cardiology (AHA/ACC) ASCVD Risk Calculator Score [ Time Frame: Baseline, Month 12 ]

    The AHA/ACC Atherosclerotic Cardiovascular Disease (ASCVD) Risk Calculator is a questionnaire that uses responses to calculate the lifetime risk of ASCVD as a percentage (0%-100%); higher percentages indicate greater lifetime risk of ASCVD. The percentages are classified as follows:

    • Low-risk (<5%)
    • Borderline risk (5% to 7.4%)
    • Intermediate risk (7.5% to 19.9%)
    • High risk (≥20%)

  9. Mean Systolic Blood Pressure [ Time Frame: Up to Month 12 ]
  10. Mean Diastolic Blood Pressure [ Time Frame: Up to Month 12 ]
  11. Percent Change in Participants Determined to be "High-Risk" for SUD per TAPS Screening Tool [ Time Frame: Baseline, Month 12 ]
    The Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS) Tool is used to assess primary care patients for tobacco, alcohol, prescription drug, and illicit substance use and problems related to their use. Based on patient responses, the tool classifies the patient risk levels as "High Risk," "Problem Use," "Undetermined Risk" and "Minimal Risk." This outcome measures the percent change in participants determined to be "High Risk" for substance abuse disorder (SUD) from baseline to Month 12.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   35 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Age 35 to 64
  2. Low SES (≤ $38,000 annual income, based on 2019 20th percentile NYC income, adjusted for family size)
  3. Expected mortality ≥1% per year (based on age, sex, race/ethnicity), with ≥1 of the following contributors:

    1. 10-year cardiovascular risk ≥10% (assessed by ASCVD risk tool)
    2. Heavy alcohol consumption (defined using SAMHSA binge drinking definition, drinking >4 standard drinks for men and >3 standard drinks for women on same occasion in past month)
  4. Willing to be navigated to Health and Hospitals Corporation of New York health system.
  5. Ability to provide written informed consent in English or Spanish

Exclusion Criteria:

  1. Receives regular care elsewhere than Health and Hospitals Corporation of New York
  2. Already diagnosed with high mortality-condition(s) that are not included in the simulation model.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05828849


Contacts
Layout table for location contacts
Contact: Ronald S Braithwaite, MD 212-263-4964 Scott.Braithwaite@nyulangone.org
Contact: Jonathan Feelemyer 301-379-9341 Jonathan.Feelemyer@nyulangone.org

Locations
Layout table for location information
United States, New York
NYC H+H/Bellevue
New York, New York, United States, 10016
Sponsors and Collaborators
NYU Langone Health
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Investigators
Layout table for investigator information
Principal Investigator: Ronald S Braithwaite, Braithwaite NYU Langone Health
Layout table for additonal information
Responsible Party: NYU Langone Health
ClinicalTrials.gov Identifier: NCT05828849    
Other Study ID Numbers: 22-01584
First Posted: April 25, 2023    Key Record Dates
Last Update Posted: March 1, 2024
Last Verified: February 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: [Dr. Ronald Scott Braithwaite, Scott.Braithwaite@nyulangone.org]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
Access Criteria: The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to Scott.Braithwaite@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases
Substance-Related Disorders
Alcoholism
Alcohol Drinking
Drinking Behavior
Chemically-Induced Disorders
Mental Disorders
Alcohol-Related Disorders